BR112019008156A2 - métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama - Google Patents
métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gamaInfo
- Publication number
- BR112019008156A2 BR112019008156A2 BR112019008156A BR112019008156A BR112019008156A2 BR 112019008156 A2 BR112019008156 A2 BR 112019008156A2 BR 112019008156 A BR112019008156 A BR 112019008156A BR 112019008156 A BR112019008156 A BR 112019008156A BR 112019008156 A2 BR112019008156 A2 BR 112019008156A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- interferon
- prevention
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 101710104976 Interferon gamma-related Proteins 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019008156A2 true BR112019008156A2 (pt) | 2019-07-02 |
Family
ID=60957345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019008156A BR112019008156A2 (pt) | 2016-10-24 | 2017-10-24 | métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (ko) |
| JP (2) | JP2019532970A (ko) |
| KR (1) | KR20190071785A (ko) |
| CN (1) | CN110167593A (ko) |
| AU (1) | AU2017352033A1 (ko) |
| BR (1) | BR112019008156A2 (ko) |
| CA (1) | CA3041434A1 (ko) |
| EA (1) | EA201990930A1 (ko) |
| IL (1) | IL266174B2 (ko) |
| MX (1) | MX2019004766A (ko) |
| SG (1) | SG11201903659WA (ko) |
| WO (1) | WO2018078442A2 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118165113A (zh) * | 2016-04-26 | 2024-06-11 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU764211C (en) * | 1998-12-01 | 2006-03-30 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| MX2007008719A (es) | 2005-01-27 | 2007-09-11 | Novimmune Sa | Anticuerpos anti-interferon gamma y metodos de uso de los mismos. |
| CN101896163A (zh) * | 2007-12-21 | 2010-11-24 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| EP2791168A1 (en) * | 2011-11-23 | 2014-10-22 | Amgen Inc. | Methods of treatment using an antibody against interferon gamma |
| KR20170018810A (ko) * | 2014-06-10 | 2017-02-20 | 메이지 세이카 파루마 가부시키가이샤 | 안정한 아달리무맙 수성 제제 |
| MX2017014294A (es) * | 2015-05-07 | 2018-08-09 | Novimmune Sa | Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores. |
-
2017
- 2017-10-24 BR BR112019008156A patent/BR112019008156A2/pt unknown
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active IP Right Cessation
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en active Pending
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 IL IL266174A patent/IL266174B2/en unknown
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en active Application Filing
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
-
2022
- 2022-10-28 JP JP2022173528A patent/JP7562074B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL266174A (en) | 2019-06-30 |
| EA201990930A1 (ru) | 2019-11-29 |
| WO2018078442A3 (en) | 2018-08-23 |
| WO2018078442A2 (en) | 2018-05-03 |
| JP7562074B2 (ja) | 2024-10-07 |
| MX2019004766A (es) | 2019-09-27 |
| AU2017352033A1 (en) | 2019-06-06 |
| IL266174B1 (en) | 2024-06-01 |
| SG11201903659WA (en) | 2019-05-30 |
| JP2019532970A (ja) | 2019-11-14 |
| CA3041434A1 (en) | 2018-05-03 |
| KR20190071785A (ko) | 2019-06-24 |
| EP3528845A2 (en) | 2019-08-28 |
| CN110167593A (zh) | 2019-08-23 |
| IL266174B2 (en) | 2024-10-01 |
| JP2022187025A (ja) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20058592A (es) | Composiciones y métodos para tratar anemia | |
| EA201792545A1 (ru) | Способы и наборы для лечения депрессии | |
| MA39906A (fr) | Polythérapies pour le traitement du cancer | |
| BR112019005305A2 (pt) | compostos espirocíclicos | |
| BR112019001615A2 (pt) | métodos e composições para tratar mielofibrose | |
| BR112017008284A8 (pt) | Bifidobactérias ativadas e métodos para uso das mesmas | |
| MX2021009899A (es) | Administracion y dosificacion de diaminofenotiazinas. | |
| BR112016029226A2 (pt) | métodos e composições para o tratamento de úlceras | |
| BR112018002550A2 (pt) | mecanismo de resistência a inibidores do bromodomínio de bet | |
| MX2018006152A (es) | Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico. | |
| BR112018008103A2 (pt) | análogos de celastrol | |
| MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
| BR112019008156A2 (pt) | métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama | |
| BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
| BR112017007817A2 (pt) | tratamento do câncer com estimuladores imunológicos | |
| NZ767902A (en) | Methods of treating ulcerative colitis | |
| BR112017021194A2 (pt) | compostos espirocíclicos | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| BR112017024163A2 (pt) | compostos bicíclicos | |
| BR112017002061A2 (pt) | composições e regimes para tratamento bucal | |
| BR112019006504A2 (pt) | regime de dosagem de avelumabe para o tratamento de câncer | |
| PH12017501120A1 (en) | Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes | |
| BR112015016992A2 (pt) | uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para o tratamento, melhoria, prevenção ou demora no progresso da fadiga | |
| BR112017004552A2 (pt) | composições farmacêuticas | |
| MX2016014780A (es) | Metodos y composiciones de dasotralina para el tratamiento del adhd. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |